Skip to content
Peptigraph home
Shop Peptides50% off*

How Tirzepatide Works: Mechanism and Pharmacology

How Tirzepatide works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.

Medical review pendingGLP-1 / GIP dual agonistUpdated
Class
GLP-1 / GIP dual agonist
FDA status
Approved (Mounjaro, Zepbound)
Routes studied
subcutaneous
Half-life
approximately 5 days
subcutaneous, in people · FDA label (Mounjaro)

How long it acts

Half-life values from FDA labels and published studies, by route. Animal values are labelled and do not describe people.

Tirzepatide half-life by route
RouteHalf-lifeMeasured inSource
subcutaneousapproximately 5 daysPeopleFDA label (Mounjaro)
subcutaneousapproximately 5-6 daysPeopleFDA label (Zepbound)
subcutaneous~5 days (population PK, 19 pooled studies)PeoplePMID 38356317

Full detail, including drug-testing windows, is on the Tirzepatide half-life page.

The receptors tirzepatide acts on

Both the Mounjaro and Zepbound labels describe tirzepatide as a GIP receptor and GLP-1 receptor agonist that selectively binds to and activates both receptors.[1]

The Zepbound label adds that GLP-1 is a physiological regulator of appetite and caloric intake, and that nonclinical studies suggest GIP may further contribute.[2]

In animals, the Zepbound label says tirzepatide distributes to and activates neurons in brain regions involved in regulating appetite and food intake.[2]

What it does in the body, per the labels

The Mounjaro label says tirzepatide enhances first- and second-phase insulin secretion and reduces glucagon levels, both in a glucose-dependent manner.[1]

It reduced fasting glucagon concentration by 28% and glucagon AUC after a mixed meal by 43% at 15 mg after 28 weeks, against no change for placebo.[1]

The label states that tirzepatide delays gastric emptying, largest after the first dose, with the effect diminishing over time.[1]

The Zepbound label says tirzepatide lowers body weight with greater fat mass loss than lean mass loss, and that the effects are likely mediated by affecting appetite.[2]

Why it is a weekly injection

The labels explain that a C20 fatty diacid enables albumin binding and prolongs the half-life.[1]

Steady-state plasma concentrations were reached after 4 weeks of once-weekly dosing, and exposure rose in proportion to dose.[2]

Mechanism checks in human trials

In SURPASS-2, tirzepatide at all doses was noninferior and superior to semaglutide on HbA1c, a comparison against a selective GLP-1 receptor agonist.[4]

An MRI substudy found liver fat fell by 8.09% with pooled tirzepatide 10 and 15 mg against 3.38% with insulin degludec.[5]

Related peptides

Tirzepatide vs SemaglutideGLP-1 agonistTirzepatide vs RetatrutideGLP-1 / GIP / glucagon triple agonistTirzepatide vs OrforglipronOral small-molecule GLP-1 agonistTirzepatide vs TesamorelinGHRH analog

Common questions

How long does Tirzepatide act in the body?

The half-life values we found are approximately 5 days (subcutaneous); approximately 5-6 days (subcutaneous). A half-life is how long the amount in the body takes to fall by half; it is not the same as how long an effect lasts.

More on Tirzepatide

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.BenefitsClaimed benefits next to what published studies measured.

Sources

  1. 1These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  2. 2These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND. ZEPBOUND ® (tirzepatide) Injection, for subcutaneous uFDA label (Zepbound), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.CPT: pharmacometrics & systems pharmacology · 2024PMID 38356317Accessed 2 Oct 2026
  4. 4Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.The New England journal of medicine · 2021PMID 34170647Accessed 2 Oct 2026
  5. 5Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.The lancet. Diabetes & endocrinology · 2022PMID 35468325Accessed 2 Oct 2026

Found an error? Report a correction.